Phase 2 Hepatitis C Clinical Trials
8 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–8 of 8 trials
Recruiting
Phase 2
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
CirrhosisCirrhosis, LiverCirrhosis Due to Hepatitis B+5 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)256 enrolled13 locationsNCT05832229
Recruiting
Phase 2
Effect of lycosomal formulations of lycopene and resveratrol chaperoned with phosphatidylcholine on progression and outcomes of Hepatitis C.
Hepatitis C
Lycotec Ltd, Cambridge, UK120 enrolled2 locationsACTRN12615000645550
Withdrawn
Phase 2
SPARTA Doublet: A Phase 2, Randomized, Double-Blind (Subject- and Investigator-Blind, Sponsor-Open), Placebo-Controlled Trial to Investigate the Safety, Tolerability, and Efficacy of ACH-0143422 in Combination with ACH-0143102 for 12, 8, or 6 Weeks in Treatment-Naive Subjects with Chronic Hepatitis C
Hepatitis C
Achillion Pharmaceuticals, Inc60 enrolled1 locationACTRN12615000390583
Completed
Phase 2
THE HEP573 STUDY: A randomised, double-blind, placebo-controlled clinical trial of silymarin alone, and silymarin combined with antioxidants in chronic hepatitis C
Chronic Hepatitis C
John Hunter Hospital216 enrolled3 locationsACTRN12614000966695
Completed
Phase 2
An open label study to investigate the safety and efficacy of treatment with ACH-0143102 and sofosbuvir in hepatitis C patients
Hepatitis C
Achillion Pharmaceuticals, Inc36 enrolled1 locationACTRN12614000307606
Completed
Phase 2
A study of the safety of 3 months treatment with BIT225, in combination with pegylated interferon and ribavirin, in patients with chronic hepatitis C infection, compared to pegylated interferon and ribavirin alone, including measurement of the concentration of BIT225 in the blood and antiviral activity.
Hepatitis C Virus Infection
Biotron Limited60 enrolled1 locationACTRN12613001296729
Completed
Phase 2
A study of the safety of BIT225 in combination with pegylated interferon and ribavirin in patients with hepatitis C virus and human immunodeficiency virus co-infection, who are naive to treatment with pegylated interferon and ribavirin, and whose HIV is currently well controlled by standard antiretroviral therapy.
Hepatitis C Virus infection in patients co-infected with human immunodeficiency virus-1
Biotron Limited12 enrolled1 locationACTRN12612001189819
Completed
Phase 2
A study of the safety of combining BIT225 with pegylated interferon and ribavirin, in patients with hepatitis C virus infection, including measurement of the concentration and distribution of BIT225 in the body and antiviral activity.
Hepatitis C Virus Infection
Biotron Limited24 enrolled1 locationACTRN12612000828820